1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
First Claim
Patent Images
1. A compound of Formula I or its pharmaceutically acceptable salt or ester, wherein:
- R2α
, R3α
, R4α
, R5α
, R6α
, R2β
, R3β
, R4β
, R5β
and R6β
are independently selected from the group consisting of hydrogen, halogen, nitro, alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, cycloalkylalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heteroaryl lower alkyl, heterocyclic, heterocyclic lower alkyl, alkylthioalkyl, cycloalkylthioalkyl, arylthio lower alkyl, aralkyl lower thioalkyl, heteroarylthio lower alkyl, heteroaralkyl lower thioalkyl, heterocyclicthio lower alkyl, heterocyclicalkyl lower thioalkyl, lower alkyl S(O)-lower alkyl, lower alkyl-S(O)2-lower alkyl, arylsulfinyl lower alkyl, arylsulfonyl lower alkyl, —
C(O)R2, R2C(O)alkyl, aminoalkyl, cycloalkylaminoalkyl, arylamino lower alkyl, heteroarylamino lower alkyl, heterocyclicamino lower alkyl, hydroxyl, hydroxyalkyl, alditol, carbohydrate, polyol alkyl, alkoxy, lower alkoxy, —
(O(CH2)2)1-3—
O-lower alkyl, polyoxyalkylene, cycloalkyloxy, cycloalkylalkoxy, haloalkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, heteroaryl lower alkoxy, heterocyclicoxy, heterocyclicalkoxy, heterocyclic lower alkoxy, —
OC(R1)2C(O)OH, —
OC(R1)2C(O)OR2, —
OC(R1)2C(O)NH2, —
OC(R1)2C(O)NHR2, —
OC(R1)2C(O)N(R2)2, —
OC(R1)2C(O)NR7R8, amino, alkylamino, acylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, heteroarylamino, heteroaralkylamino, heterocyclicamino, heterocyclicalkylamino, —
NHR2, N(R2)2, —
NR7R8, —
NHC(R1)2C(O)OH, —
NHC(R1)2C(O)OR2, —
NHC(O)R2, —
N(R2)C(O)R2, —
NHC(O)OR2, —
NHC(O)SR2, —
NHSO2NHR2, —
NHSO2R2, —
NHSO2NR7R8, —
N(C(O)NHR2)2, —
NR2SO2R2, —
NHC(O)NHR2, —
NHC(O)NR7R8, —
NHC(O)N(R2)2, thiol, alkylthio, cycloalkylthio, cycloalkylalkylthio, haloalkylthio, arylthio, aralkylthio, heteroarylthio, heteroaralkylthio, heterocyclicthio, heterocyclicalkylthio, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, —
SC(R1)2C(O)OH, —
SC(R1)2C(O)OR2, —
SCH2C(O)OH, —
SCF2C(O)OH, —
SO2NH2, —
SO2NHR2, —
SO2N(R2)2, SO2NR7R8, —
SO2NHC(O)R2, —
SR2, —
SO2NHC(O)NHR2, —
SO2NHC(O)N(R2) 2, —
SO2NHC(O)NR7R8, sulfonic acid, sulfonate, sulfate, sulfinic acid, sulfenic acid, cyano, tetrazol-5-yl, carboxy, —
C(O)OR2, —
C(O)NH2, —
C(O)NHR2, —
C(O)N(R2)2, —
C(O)NR7R8, —
C(O)NHC(O)R2, —
C(O)NHC(O)NHR2, —
C(O)NHC(O)N(R2)2, —
C(O)NHC(O)NR7R8, —
C(O)NHSO2R2, —
C(O)NHSO2NHR2, —
C(O)NHSO2N(R2), —
C(O)NHSO2NR7R8—
C(CH3)2C(O)OH, —
(CH2)yC(O)OH, wherein y is 1, 2, 3, 4, 5, or 6, —
PO2H2, —
PO3H2, —
P(R2)O2H, and phosphate, all of which can be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R1 is independently selected from the group consisting of hydrogen, lower alkyl, carbocycle, cycloalkyl, aryl, heteroaryl, heterocyclic, arylalkyl, heteroarylalkyl, and heterocyclicalkyl, wherein all may be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R2 is independently selected from the group consisting of alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, aryl, heteroaryl, heterocyclic, arylalkyl, heteroarylalkyl, and heterocyclicalkyl, wherein all may be substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R7 and R8 are independently selected from the group consisting of alkyl, alkenyl, heteroaryl and aryl and linked together forming a 4- to 12-membered monocyclic, bicylic, tricyclic or benzofused ring;
wherein one of R2β
, R3β
, R4β
, R5β
or R6β
, or one of R2α
, R3α
, R4α
, R5α
or R6α
must be a carbon-carbon linked heterocyclic or heteroaryl;
or R2α
and R3α
taken together or R3α
and R4α
taken together or R4α
and R5α
taken together, or R2β
and R3α
taken together or R3α
and R4α
taken together or R4α
and R5α
taken together form a heterocyclic or heteroaryl optionally substituted by one or more alkoxycarbonylalkyl, carboxyalkyl, hydroxyalkyl or aminoalkyl and optionally substituted where possible with one or more selected from the group consisting of hydroxy, alkyl, carboxy, hydroxyalkyl, carboxyalkyl, amino, cyano, alkoxy, alkoxycarbonyl, acyl, oxo, —
NR7R8, and halo;
or R2α
and R3α
taken together or R3α
and R4α
taken together or R4α
and R5α
taken together or R2β
and R3β
taken together or R3β
and R4β
taken together or R4β
and R5α
taken together form a 5- or 6-membered ring containing one nitrogen, which may optionally be substituted where possible with one or more selected from the group consisting of halo, alkyl, lower alkyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
wherein all R1, R2, R7 and R8 substituents can be optionally substituted where possible with one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention relates to compounds, pharmaceutical compositions and methods of using compounds of the general formula
-
Citations
37 Claims
-
1. A compound of Formula I
or its pharmaceutically acceptable salt or ester, wherein: -
R2α
, R3α
, R4α
, R5α
, R6α
, R2β
, R3β
, R4β
, R5β
and R6β
are independently selected from the group consisting of hydrogen, halogen, nitro, alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, cycloalkylalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heteroaryl lower alkyl, heterocyclic, heterocyclic lower alkyl, alkylthioalkyl, cycloalkylthioalkyl, arylthio lower alkyl, aralkyl lower thioalkyl, heteroarylthio lower alkyl, heteroaralkyl lower thioalkyl, heterocyclicthio lower alkyl, heterocyclicalkyl lower thioalkyl, lower alkyl S(O)-lower alkyl, lower alkyl-S(O)2-lower alkyl, arylsulfinyl lower alkyl, arylsulfonyl lower alkyl, —
C(O)R2, R2C(O)alkyl, aminoalkyl, cycloalkylaminoalkyl, arylamino lower alkyl, heteroarylamino lower alkyl, heterocyclicamino lower alkyl, hydroxyl, hydroxyalkyl, alditol, carbohydrate, polyol alkyl, alkoxy, lower alkoxy, —
(O(CH2)2)1-3—
O-lower alkyl, polyoxyalkylene, cycloalkyloxy, cycloalkylalkoxy, haloalkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, heteroaryl lower alkoxy, heterocyclicoxy, heterocyclicalkoxy, heterocyclic lower alkoxy, —
OC(R1)2C(O)OH, —
OC(R1)2C(O)OR2, —
OC(R1)2C(O)NH2, —
OC(R1)2C(O)NHR2, —
OC(R1)2C(O)N(R2)2, —
OC(R1)2C(O)NR7R8, amino, alkylamino, acylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, heteroarylamino, heteroaralkylamino, heterocyclicamino, heterocyclicalkylamino, —
NHR2, N(R2)2, —
NR7R8, —
NHC(R1)2C(O)OH, —
NHC(R1)2C(O)OR2, —
NHC(O)R2, —
N(R2)C(O)R2, —
NHC(O)OR2, —
NHC(O)SR2, —
NHSO2NHR2, —
NHSO2R2, —
NHSO2NR7R8, —
N(C(O)NHR2)2, —
NR2SO2R2, —
NHC(O)NHR2, —
NHC(O)NR7R8, —
NHC(O)N(R2)2, thiol, alkylthio, cycloalkylthio, cycloalkylalkylthio, haloalkylthio, arylthio, aralkylthio, heteroarylthio, heteroaralkylthio, heterocyclicthio, heterocyclicalkylthio, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, —
SC(R1)2C(O)OH, —
SC(R1)2C(O)OR2, —
SCH2C(O)OH, —
SCF2C(O)OH, —
SO2NH2, —
SO2NHR2, —
SO2N(R2)2, SO2NR7R8, —
SO2NHC(O)R2, —
SR2, —
SO2NHC(O)NHR2, —
SO2NHC(O)N(R2) 2, —
SO2NHC(O)NR7R8, sulfonic acid, sulfonate, sulfate, sulfinic acid, sulfenic acid, cyano, tetrazol-5-yl, carboxy, —
C(O)OR2, —
C(O)NH2, —
C(O)NHR2, —
C(O)N(R2)2, —
C(O)NR7R8, —
C(O)NHC(O)R2, —
C(O)NHC(O)NHR2, —
C(O)NHC(O)N(R2)2, —
C(O)NHC(O)NR7R8, —
C(O)NHSO2R2, —
C(O)NHSO2NHR2, —
C(O)NHSO2N(R2), —
C(O)NHSO2NR7R8—
C(CH3)2C(O)OH, —
(CH2)yC(O)OH, wherein y is 1, 2, 3, 4, 5, or 6, —
PO2H2, —
PO3H2, —
P(R2)O2H, and phosphate, all of which can be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R1 is independently selected from the group consisting of hydrogen, lower alkyl, carbocycle, cycloalkyl, aryl, heteroaryl, heterocyclic, arylalkyl, heteroarylalkyl, and heterocyclicalkyl, wherein all may be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R2 is independently selected from the group consisting of alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, aryl, heteroaryl, heterocyclic, arylalkyl, heteroarylalkyl, and heterocyclicalkyl, wherein all may be substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R7 and R8 are independently selected from the group consisting of alkyl, alkenyl, heteroaryl and aryl and linked together forming a 4- to 12-membered monocyclic, bicylic, tricyclic or benzofused ring;
wherein one of R2β
, R3β
, R4β
, R5β
or R6β
, or one of R2α
, R3α
, R4α
, R5α
or R6α
must be a carbon-carbon linked heterocyclic or heteroaryl;
orR2α
and R3α
taken together or R3α
and R4α
taken together or R4α
and R5α
taken together, or R2β
and R3α
taken together or R3α
and R4α
taken together or R4α
and R5α
taken together form a heterocyclic or heteroaryl optionally substituted by one or more alkoxycarbonylalkyl, carboxyalkyl, hydroxyalkyl or aminoalkyl and optionally substituted where possible with one or more selected from the group consisting of hydroxy, alkyl, carboxy, hydroxyalkyl, carboxyalkyl, amino, cyano, alkoxy, alkoxycarbonyl, acyl, oxo, —
NR7R8, and halo;
orR2α
and R3α
taken together or R3α
and R4α
taken together or R4α
and R5α
taken together or R2β
and R3β
taken together or R3β
and R4β
taken together or R4β
and R5α
taken together form a 5- or 6-membered ring containing one nitrogen, which may optionally be substituted where possible with one or more selected from the group consisting of halo, alkyl, lower alkyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
wherein all R1, R2, R7 and R8 substituents can be optionally substituted where possible with one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)
-
2. The compound of claim 1 or its pharmaceutically acceptable salt or ester, wherein:
-
R2α
, R3α
, R4α
, R5α
, R6α
, R2β
, R3β
, R4β
, R5β
and R6β
are independently selected from the group consisting of hydrogen, halogen, nitro, alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, cycloalkylalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heteroaryl lower alkyl, heterocyclic, heterocyclic lower alkyl, alkylthioalkyl, cycloalkylthioalkyl, arylthio lower alkyl, aralkyl lower thioalkyl, heteroarylthio lower alkyl, heteroaralkyl lower thioalkyl, heterocyclicthio lower alkyl, heterocyclicalkyl lower thioalkyl, lower alkyl S(O)-lower alkyl, lower alkyl-S(O)2-lower alkyl, arylsulfinyl lower alkyl, arylsulfonyl lower alkyl, —
C(O)R2, R2C(O)alkyl, aminoalkyl, cycloalkylaminoalkyl, arylamino lower alkyl, heteroarylamino lower alkyl, heterocyclicamino lower alkyl, hydroxyl, hydroxyalkyl, alkoxy, lower alkoxy, —
(O(CH2)2)1-3—
O-lower alkyl, cycloalkyloxy, cycloalkylalkoxy, haloalkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, heteroaryl lower alkoxy, heterocyclicoxy, heterocyclicalkoxy, heterocyclic lower alkoxy, —
OC(R1)2C(O)OH, —
OC(R1)2C(O)OR2, —
OC(R1)2C(O)NH2, —
OC(R1)2C(O)NHR2, —
OC(R1)2C(O)N(R2)2, —
OC(R1)2C(O)NR7R8, amino, alkylamino, acylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, heteroarylamino, heteroaralkylamino, heterocyclicamino, heterocyclicalkylamino, —
NHR2, N(R2)2, —
NR7R8, —
NHC(R1)2C(O)OH, —
NHC(R1)2C(O)OR2, —
NHC(O)R2, —
N(R2)C(O)R2, —
NHC(O)OR2, —
NHC(O)SR2, —
NHSO2NHR2, —
NHSO2R2, —
NHSO2NR R, —
N(C(O)NHR2)2, —
NR2SO2R2, —
NHC(O)NHR2, —
NHC(O)NR7R2, —
NHC(O)N(R2)2, thiol, alkylthio, cycloalkylthio, cycloalkylalkylthio, haloalkylthio, arylthio, aralkylthio, heteroarylthio, heteroaralkylthio, heterocyclicthio, heterocyclicalkylthio, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, —
SC(R1)2C(O)OH, —
SC(R1)2C(O)OR2, —
SCH2C(O)OH, SCF2C(O)OH, —
SO2NH2, —
SO2NHR2, —
SO2N(R2)2, SO2NR2, —
SO2NHC(O)R2, —
SR2, —
SO2NHC(O)NHR2, —
SO2NHC(O)N(R2)2, —
SO2NHC(O)NR7R8, sulfonic acid, sulfonate, sulfate, sulfinic acid, sulfenic acid, cyano, tetrazol-5-yl, carboxy, —
C(O)OR2, —
C(O)NH2, —
C(O)NHR2, —
C(O)N(R2)2, —
C(O)NR7R8, —
C(O)NHC(O)R2, —
C(O)NHC(O)NHR2, —
C(O)NHC(O)N(R2)2, —
C(O)NHC(O)NR7R8, —
C(O)NHSO2R2, —
C(O)NHSO2NHR2, —
C(O)NHSO2N(R2), —
C(O)NHSO2NR7R8, —
C(CH3)2C(O)OH, —
(CH2)yC(O)OH, wherein y is 1, 2, 3, 4, 5, or 6, —
PO2H2, —
PO3H2, —
P(R2)O2H, and phosphate, all of which can be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R1 is independently selected from the group consisting of hydrogen, lower alkyl, carbocycle, cycloalkyl, aryl, heteroaryl, heterocyclic, arylalkyl, heteroarylalkyl, and heterocyclicalkyl, wherein all may be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R1)2;
R2 is independently selected from the group consisting of alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, aryl, heteroaryl, heterocyclic, arylalkyl, heteroarylalkyl, and heterocyclicalkyl, wherein all may be substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R7 and R8 are independently selected from the group consisting of alkyl, alkenyl, heteroaryl and aryl and linked together forming a 4- to 12-membered monocyclic, bicylic, tricyclic or benzofused ring;
wherein one of R2β
, R3β
, R4β
, R5β
or R6β
, or one of R2α
, R3α
, R4α
, R5α
or R6α
must be a carbon-carbon linked heterocyclic or heteroaryl;
wherein all R1, R2, R7 and R8 substituents can be optionally substituted where possible with one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2.
-
-
3. The compound of claim 2 or its pharmaceutically acceptable salt or ester, wherein:
-
R2α
, R3α
, R4α
, R5α
, R6α
, R2β
, R3β
, R4β
, R5β
and R6β
are independently selected from the group consisting of hydrogen, halogen, nitro, alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, cycloalkylalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heteroaryl lower alkyl, heterocyclic, heterocyclic lower alkyl, alkylthioalkyl, cycloalkylthioalkyl, arylthio lower alkyl, aralkyl lower thioalkyl, heteroarylthio lower alkyl, heteroaralkyl lower thioalkyl, heterocyclicthio lower alkyl, heterocyclicalkyl lower thioalkyl, —
C(O)R2, R2C(O)alkyl, aminoalkyl, cycloalkylaminoalkyl, arylamino lower alkyl, heteroarylamino lower alkyl, heterocyclicamino lower alkyl, hydroxyl, hydroxyalkyl, alkoxy, lower alkoxy, —
(O(CH2)2)1-3—
O-lower alkyl, cycloalkyloxy, cycloalkylalkoxy, haloalkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, heteroaryl lower alkoxy, heterocyclicoxy, heterocyclicalkoxy, heterocyclic lower alkoxy, —
OC(R1)2C(O)OH, —
OC(R1)2C(O)OR2, —
OC(R1)2C(O)NH2, —
OC(R1)2C(O)NHR2, —
OC(R1)2C(O)N(R2)2, —
OC(R1)2C(O)NR7R8, amino, alkyl amino, acylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, heteroarylamino, heteroaralkylamino, heterocyclicamino, heterocyclicalkylamino, —
NHR2, N(R2)2, —
NR7R8, —
NHC(R1)2C(O)OH, —
NHC(R1)2C(O)OR2, —
NHC(O)R2, —
N(R2)C(O)R2, —
NHC(O)OR2, —
NHC(O)SR2, —
NHSO2NHR2, —
NHSO2R2, —
NHSO2NR7R8, —
N(C(O)NHR2)2, —
NR2SO2R2, —
NHC(O)NHR2, —
NHC(O)NR7R8, —
NHC(O)N(R2)2, thiol, alkylthio, cycloalkylthio, cycloalkylalkylthio, haloalkylthio, arylthio, aralkylthio, heteroarylthio, heteroaralkylthio, heterocyclicthio, heterocyclicalkylthio, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, —
SC(R1)2C(O)OH, —
SC(R1)2C(O)OR2, —
SCH2C(O)OH, —
SCF2C(O)OH, —
SO2NH2, —
SO2NHR2, —
SO2N(R2)2, SO2NR7R8, —
SO2NHC(O)R2, —
SR2, —
SO2NHC(O)NHR2, —
SO2NHC(O)N(R2) 2, —
SO2NHC(O)NR7R8, sulfonic acid, sulfonate, sulfate, sulfinic acid, sulfenic acid, cyano, tetrazol-5-yl, carboxy, —
C(O)OR2, —
C(O)NH2, —
C(O)NHR2, —
C(O)N(R2)2, —
C(O)NR7R8, —
C(O)NHC(O)R2, —
C(O)NHC(O)NHR2, —
C(O)NHC(O)N(R2)2, —
C(O)NHC(O)NR7R8, —
C(O)NHSO2R2, —
C(O)NHSO2NHR2, —
C(O)NHSO2N(R2), —
C(O)NHSO2NR7R8, —
C(CH3)2C(O)OH, —
(CH2)yC(O)OH, wherein y is 1, 2, 3, 4, 5, or 6, —
PO2H2, —
PO3H2, —
P(R2)O2H, and phosphate, all of which can be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R1 is independently selected from the group consisting of hydrogen, lower alkyl, carbocycle, cycloalkyl, aryl, heteroaryl, heterocyclic, arylalkyl, heteroarylalkyl, and heterocyclicalkyl, wherein all may be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R2 is independently selected from the group consisting of alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, aryl, heteroaryl, heterocyclic, arylalkyl, heteroarylalkyl, and heterocyclicalkyl, wherein all may be substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R7 and R8 are independently selected from the group consisting of alkyl, alkenyl, heteroaryl and aryl and linked together forming a 4- to 12-membered monocyclic, bicylic, tricyclic or benzofused ring;
wherein one of R2β
, R3β
, R4β
, R5β
or R6β
, or one of R2α
, R3α
, R4α
, R5α
or R6α
must be a carbon-carbon linked heteroaryl;
wherein all R1, R2, R7 and R8 substituents can be optionally substituted where possible with one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2.
-
-
4. The compound of claim 1 or its pharmaceutically acceptable salt or ester, wherein:
-
R3α
, R4α
, R5α
, R2β
, R3β
, R4β
, R5β
and R6β
are independently selected from the group consisting of hydrogen, halogen, nitro, alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, cycloalkylalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heteroaryl lower alkyl, heterocyclic, heterocyclic lower alkyl, alkylthioalkyl, cycloalkylthioalkyl, arylthio lower alkyl, aralkyl lower thioalkyl, heteroarylthio lower alkyl, heteroaralkyl lower thioalkyl, heterocyclicthio lower alkyl, heterocyclicalkyl lower thioalkyl, —
C(O)R2, R2C(O)alkyl, aminoalkyl, cycloalkylaminoalkyl, arylamino lower alkyl, heteroarylamino lower alkyl, heterocyclicamino lower alkyl, hydroxyl, hydroxyalkyl, alkoxy, lower alkoxy, —
(O(CH2)2)1-3—
O-lower alkyl, cycloalkyloxy, cycloalkylalkoxy, haloalkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, heteroaryl lower alkoxy, heterocyclicoxy, heterocyclicalkoxy, heterocyclic lower alkoxy, —
OC(R1)2C(O)OH, —
OC(R1)2C(O)OR2, —
OC(R1)2C(O)NH2, —
OC(R1)2C(O)NHR2, —
OC(R1)2C(O)N(R2)2, —
OC(R1)2C(O)NR7R8, amino, alkylamino, acylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, heteroarylamino, heteroaralkylamino, heterocyclicamino, heterocyclicalkylamino, —
NHR2, N(R2)2, —
NR R, —
NHC(R1)2C(O)OH, —
NHC(R1)2C(O)OR2, —
NHC(O)R2, —
N(R2)C(O)R2, —
NHC(O)OR2, —
NHC(O)SR2, —
NHSO2NHR2, —
NHSO2R2, —
NHSO2NR7R8, —
N(C(O)NHR2)2, —
NR2SO2R2, —
NHC(O)NHR2, —
NHC(O)NR7R8, —
NHC(O)N(R2)2, thiol, alkylthio, cycloalkylthio, cycloalkylalkylthio, haloalkylthio, arylthio, aralkylthio, heteroarylthio, heteroaralkylthio, heterocyclicthio, heterocyclicalkylthio, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, —
SC(R1)2C(O)OH, —
SC(R1)2C(O)OR2, —
SCH2C(O)OH, —
SCF2C(O)OH, —
SO2NH2, —
SO2NHR2, —
SO2N(R2)2, SO2NR7R8, —
SO2NHC(O)R2, —
SR2, —
SO2NHC(O)NHR2, —
SO2NHC(O)N(R2)2, —
SO2NHC(O)NR7R8, sulfonic acid, sulfonate, sulfate, sulfinic acid, sulfenic acid, cyano, tetrazol-5-yl, carboxy, —
C(O)OR2, —
C(O)NH2, —
C(O)NHR2, —
C(O)N(R2)2, —
C(O)NR7R8, —
C(O)NHC(O)R2, —
C(O)NHC(O)NHR2, —
C(O)NHC(O)N(R2)2, —
C(O)NHC(O)NR7R8, —
C(O)NHSO2R2, —
C(O)NHSO2NHR2, —
C(O)NHSO2N(R2), —
C(O)NHSO2NR7R8, —
C(CH3)2C(O)OH, —
(CH2)yC(O)OH, wherein y is 1, 2, 3, 4, 5, or 6, —
PO2H2, —
PO3H2, —
P(R2)O2H, and phosphate, all of which can be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R2α
and R6α
are independently selected from the group consisting of halogen, nitro, alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, cycloalkylalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heteroaryl lower alkyl, heterocyclic, heterocyclic lower alkyl, alkylthioalkyl, cycloalkylthioalkyl, arylthio lower alkyl, aralkyl lower thioalkyl, heteroarylthio lower alkyl, heteroaralkyl lower thioalkyl, heterocyclicthio lower alkyl, heterocyclicalkyl lower thioalkyl, R2C(O)alkyl, aminoalkyl, cycloalkylaminoalkyl, arylamino lower alkyl, heteroarylamino lower alkyl, heterocyclicamino lower alkyl, hydroxyalkyl, alkoxy, lower alkoxy, —
(O(CH2)2)1-3—
O-lower alkyl, cycloalkyloxy, cycloalkylalkoxy, haloalkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, heteroaryl lower alkoxy, heterocyclicoxy, heterocyclicalkoxy, heterocyclic lower alkoxy, —
OC(R1)2C(O)OH, —
OC(R1)2C(O)OR2, —
OC(R1)2C(O)NH2, —
OC(R1)2C(O)NHR2, —
OC(R1)2C(O)N(R2)2, —
OC(R1)2C(O)NR7R8, —
NHSO2NHR2, —
NHSO2R2, —
NHSO2NR7R8, —
NR2SO2R2, alkylthio, cycloalkylthio, cycloalkylalkylthio, haloalkylthio, arylthio, aralkylthio, heteroarylthio, heteroaralkylthio, heterocyclicthio, heterocyclicalkylthio, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, —
SC(R1)2C(O)OH, —
SC(R1)2C(O)OR2, —
SCH2C(O)OH, —
SCF2C(O)OH, —
SO2NH2, —
SO2NHR2, —
SO2N(R2)2, SO2NR7R8, —
SO2NHC(O)R2, —
SR2, —
SO2NHC(O)NHR2, —
SO2NHC(O)N(R2) 2, —
SO2NHC(O)NR7R8, sulfonic acid, sulfonate, sulfate, sulfinic acid, sulfenic acid, cyano, tetrazol-5-yl, carboxy, —
C(O)OR2, —
C(O)NH2, —
C(O)NHR2, —
C(O)N(R2)2, —
C(O)NR7R8, —
C(O)NHC(O)R2, —
C(O)NHC(O)NHR2, —
C(O)NHC(O)N(R2)2, —
C(O)NHC(O)NR7R8, —
C(O)NHSO2R2, —
C(O)NHSO2NHR2, —
C(O)NHSO2N(R2), —
C(O)NHSO2NR7R8, —
C(CH3)2C(O)OH, —
(CH2)yC(O)OH, wherein y is 1, 2, 3, 4, 5, or 6, —
PO2H2, —
PO3H2, —
P(R2)O2H, and phosphate, all of which can be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R1 is independently selected from the group consisting of hydrogen, lower alkyl, carbocycle, cycloalkyl, aryl, heteroaryl, heterocyclic, arylalkyl, heteroarylalkyl, and heterocyclicalkyl, wherein all may be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R2 is independently selected from the group consisting of alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, aryl, heteroaryl, heterocyclic, arylalkyl, heteroarylalkyl, and heterocyclicalkyl, wherein all may be substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R7 and R8 are independently selected from the group consisting of alkyl, alkenyl, heteroaryl and aryl and linked together forming a 4- to 12-membered monocyclic, bicylic, tricyclic or benzofused ring;
wherein one of R2β
, R3β
, R4β
, R5β
or R6β
, or one of R2α
, R3α
, R4α
, R5α
or R6α
must be a carbon-carbon linked heteroaryl;
wherein all R1, R2, R7 and R8 substituents can be optionally substituted where possible with one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2.
-
-
5. The compound of claim 4 or its pharmaceutically acceptable salt or ester, wherein:
-
R3α
, R4α
, R5α
, R2β
, R3β
, R4β
, R5β
and R6β
are independently selected from the group consisting of hydrogen, halogen, nitro, alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, cycloalkylalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heteroaryl lower alkyl, heterocyclic, heterocyclic lower alkyl, alkylthioalkyl, cycloalkylthioalkyl, arylthio lower alkyl, aralkyl lower thioalkyl, heteroarylthio lower alkyl, heteroaralkyl lower thioalkyl, heterocyclicthio lower alkyl, heterocyclicalkyl lower thioalkyl, —
C(O)R2, R2C(O)alkyl, aminoalkyl, cycloalkylaminoalkyl, arylamino lower alkyl, heteroarylamino lower alkyl, heterocyclicamino lower alkyl, hydroxyl, hydroxyalkyl, alkoxy, lower alkoxy, —
(O(CH2)2)1-3—
O-lower alkyl, cycloalkyloxy, cycloalkylalkoxy, haloalkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, heteroaryl lower alkoxy, heterocyclicoxy, heterocyclicalkoxy, heterocyclic lower alkoxy, —
OC(R1)2C(O)OH, —
OC(R1)2C(O)OR2, —
OC(R1)2C(O)NH2, —
OC(R1)2C(O)NHR2, —
OC(R1)2C(O)N(R2)2, —
OC(R1)2C(O)NR7R8, amino, alkylamino, acylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, heteroarylamino, heteroaralkylamino, heterocyclicamino, heterocyclicalkylamino, —
NHR2, N(R2)2, —
NR7R8, —
NHC(R1)2C(O)OH, —
NHC(R1)2C(O)OR2, —
NHC(O)R2, —
N(R2)C(O)R2, —
NHC(O)OR2, —
NHC(O)SR2, —
NHSO2NHR2, —
NHSO2R2, —
NHSO2NR7R8, —
N(C(O)NHR2)2, —
NR2SO2R2, —
NHC(O)NHR2, —
NHC(O)NR7R8, —
NHC(O)N(R2)2, thiol, alkylthio, cycloalkylthio, cycloalkylalkylthio, haloalkylthio, arylthio, aralkylthio, heteroarylthio, heteroaralkylthio, heterocyclicthio, heterocyclicalkylthio, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, —
SC(R1)2C(O)OH, —
SC(R1)2C(O)OR2, —
SCH2C(O)OH, —
SCF2C(O)OH, —
SO2NH2, SO2NHR2, —
SO2N(R2)2, SO2NR7R8, —
SO2NHC(O)R2, —
SR2, —
SO2NHC(O)NHR2, —
SO2NHC(O)N(R2)2, —
SO2NHC(O)NR7R8, sulfonic acid, sulfonate, sulfate, sulfinic acid, sulfenic acid, cyano, tetrazol-5-yl, carboxy, —
C(O)OR2, —
C(O)NH2, —
C(O)NHR2, —
C(O)N(R2)2, —
C(O)NR7R8, —
C(O)NHC(O)R2, —
C(O)NHC(O)NHR2, —
C(O)NHC(O)N(R2)2, —
C(O)NHC(O)NR7R8, —
C(O)NHSO2R2, —
C(O)NHSO2NHR2, —
C(O)NHSO2N(R), —
C(O)NHSO2NR7R8, —
C(CH3)2C(O)OH, —
(CH2)yC(O)OH, wherein y is 1, 2, 3, 4, 5, or 6, —
PO2H2, —
PO3H2, —
P(R2)O2H, and phosphate, all of which can be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R2α
and R6α
are independently selected from the group consisting of halogen, nitro, alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heteroaryl lower alkyl, heterocyclic, heterocyclic lower alkyl, R2C(O)alkyl, aminoalkyl, cycloalkylaminoalkyl, arylamino lower alkyl, heteroarylamino lower alkyl, heterocyclicamino lower alkyl, hydroxyalkyl, alkoxy, lower alkoxy, cycloalkyloxy, cycloalkylalkoxy, haloalkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, heteroaryl lower alkoxy, heterocyclicoxy, heterocyclicalkoxy, heterocyclic lower alkoxy, —
OC(R1)2C(O)OH, —
OC(R1)2C(O)OR2, —
OC(R1)2C(O)NH2, —
OC(R1)2C(O)NHR2, —
OC(R1)2C(O)N(R2)2, —
OC(R1)2C(O)NR7R8, —
NHSO2NHR2, —
NHSO2R, —
NHSO2NR7R8, —
NR2SO2R2, alkylthio, cycloalkylthio, —
SC(R1)2C(O)OH, —
SC(R1)2C(O)OR2, —
SCH2C(O)OH, —
SCF2C(O)OH, —
SO2NHR2, —
SO2NHR2, —
SO2N(R2)2, SO2NR7R8, —
SO2NHC(O)R2, —
SR2, —
SO2NHC(O)NHR2, —
SO2NHC(O)N(R2) 2, —
SO2NHC(O)NR7R8, cyano, tetrazol-5-yl, carboxy, —
C(O)OR2, —
C(O)NH2, —
C(O)NHR2, —
C(O)N(R2)2, —
C(O)NR7R8, —
C(O)NHC(O)R2, —
C(O)NHC(O)NHR2, —
C(O)NHC(O)N(R2)2, —
C(O)NHC(O)NR7R8, —
C(O)NHSO2R2, —
C(O)NHSO2NHR2, —
C(O)NHSO2N(R2), —
C(O)NHSO2N7R8, —
C(CH3)2C(O)OH, —
(CH2)yC(O)OH, wherein y is 1, 2, 3, 4, 5, or 6, all of which can be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R1 is independently selected from the group consisting of hydrogen, lower alkyl, carbocycle, cycloalkyl, aryl, heteroaryl, heterocyclic, arylalkyl, heteroarylalkyl, and heterocyclicalkyl, wherein all may be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R2 is independently selected from the group consisting of alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, aryl, heteroaryl, heterocyclic, arylalkyl, heteroarylalkyl, and heterocyclicalkyl, wherein all may be substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R7 and R8 are independently selected from the group consisting of alkyl, alkenyl, heteroaryl and aryl and linked together forming a 4- to 12-membered monocyclic, bicylic, tricyclic or benzofused ring;
wherein one of R2α
, R3α
, R4α
, R5α
or R6α
must be a carbon-carbon linked heteroaryl;
wherein all R1, R2, R7 and R8 substituents can be optionally substituted where possible with one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2.
-
-
6. The compound of claim 5 or its pharmaceutically acceptable salt or ester, wherein:
-
R3α
, R4α
, R5α
, R2β
, R3β
, R4β
, R5β
and R6β
are independently selected from the group consisting of hydrogen, halogen, nitro, alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, cycloalkylalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heteroaryl lower alkyl, heterocyclic, heterocyclic lower alkyl, R2C(O)alkyl, aminoalkyl, hydroxyl, hydroxyalkyl, alkoxy, lower alkoxy, cycloalkyloxy, haloalkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, —
OC(R1)2C(O)OH, —
OC(R1)2C(O)OR2, —
OC(R1)2C(O)NH2, —
OC(R1)2C(O)NHR2, —
OC(R1)2C(O)N(R2)2, —
OC(R1)2C(O)NR7R8, amino, alkylamino, acylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, heteroarylamino, heteroaralkylamino, heterocyclicamino, heterocyclicalkylamino, NHR2, N(R2)2, —
NR7R8, —
NHC(R1)2C(O)OH, —
NHC(R1)2C(O)OR2, —
NHC(O)R2, —
N(R2)C(O)R2, —
NHC(O)OR2, —
NHC(O)SR2, —
NHSO2NHR2, —
NHSO2R2, —
NHSO2NR7R8, —
N(C(O)NHR2)2, —
NR2SO2, —
NHC(O)NHR2, —
NHC(O)NR7R8, —
NHC(O)N(R2)2, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, —
SC(R1)2C(O)OH, —
SC(R1)2C(O)OR2, —
SCH2C(O)OH, —
SCF2C(O)OH, —
SO2NH2, —
SO2NHR2, —
SO2N(R2)2, SO2NR7R8, —
SO2NHC(O)R2, —
SR2, —
SO2NHC(O)NHR2, —
SO2NHC(O)N(R2) 2, —
SO2NHC(O)NR7R8, cyano, tetrazol-5-yl, carboxy, —
C(O)OR2, —
C(O)NH2, —
C(O)NHR2, —
C(O)N(R2)2, —
C(O)NR7R8, C(O)NHC(O)R2, —
C(O)NHC(O)NHR2, —
C(O)NHC(O)N(R2)2, —
C(O)NHC(O)NR7R8, —
C(O)NHSO2R2, —
C(O)NHSO2NHR2, —
C(O)NHSO2N(R2), —
C(O)NHSO2NR7R8, —
C(CH3)2C(O)OH, all of which can be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R2α
and R6α
are independently selected from the group consisting of halogen, nitro, alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heteroaryl lower alkyl, heterocyclic, heterocyclic lower alkyl, R2C(O)alkyl, aminoalkyl, hydroxyalkyl, alkoxy, lower alkoxy, cycloalkyloxy, cycloalkylalkoxy, haloalkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, heteroaryl lower alkoxy, heterocyclicoxy, heterocyclicalkoxy, heterocyclic lower alkoxy, —
OC(R1)2C(O)OH, —
OC(R1)2C(O)OR2, —
OC(R1)2C(O)NH2, —
OC(R1)2C(O)NHR2, —
OC(R1)2C(O)N(R2)2, —
OC(R1)2C(O)NR7R8, —
SC(R1)2C(O)OH, —
SC(R1)2C(O)OR2, —
SCH2C(O)OH, —
SCF2C(O)OH, —
SO2NH2, —
SO2NHR2, —
SO2N(R2)2, SO2NR7R8, —
SO2NHC(O)R2, —
SR2, —
SO2NHC(O)NHR2, —
SO2NHC(O)N(R2)2, —
SO2NHC(O)NR7R8, all of which can be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R1 is independently selected from the group consisting of hydrogen, lower alkyl, carbocycle, cycloalkyl, aryl, heteroaryl, heterocyclic, arylalkyl, heteroarylalkyl, and heterocyclicalkyl, wherein all may be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R2 is independently selected from the group consisting of alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, aryl, heteroaryl, heterocyclic, arylalkyl, heteroarylalkyl, and heterocyclicalkyl, wherein all may be substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R7 and R8 are independently selected from the group consisting of alkyl, alkenyl, heteroaryl and aryl and linked together forming a 4- to 12-membered monocyclic, bicylic, tricyclic or benzofused ring;
wherein one of R2α
, R3α
, R4α
, R5α
or R6α
must be a carbon-carbon linked heteroaryl;
wherein all R1, R2, R7 and R8 substituents can be optionally substituted where possible with one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2.
-
-
7. The compound of claim 6 or its pharmaceutically acceptable salt or ester, wherein:
-
R3α
, R4α
, R5α
, R2β
, R3β
, R4β
, R5β
and R6β
are independently selected from the group consisting of hydrogen, halogen, nitro, alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, cycloalkylalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heteroaryl lower alkyl, heterocyclic, heterocyclic lower alkyl, R2C(O)alkyl, aminoalkyl, hydroxyl, hydroxyalkyl, alkoxy, lower alkoxy, cycloalkyloxy, haloalkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, —
OC(R1)2C(O)OH, —
OC(R1)2C(O)OR2, —
OC(R1)2C(O)NH2, —
OC(R1)2C(O)NHR2, —
OC(R1)2C(O)N(R2)2, —
OC(R1)2C(O)NR7R8, amino, alkylamino, acylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, heteroarylamino, heteroaralkylamino, heterocyclicamino, heterocyclicalkylamino, —
NHR2, N(R2)2, —
NR7R8, —
NHC(R1)2C(O)OH, —
NHC(R1)2C(O)OR2, —
NHC(O)R2, —
N(R2)C(O)R2, —
NHC(O)OR2, —
NHC(O)SR2, —
NHSO2NHR2, —
NHSO2R2, —
NHSO2NR7R8, —
N(C(O)NHR2)2, —
NR2SO2R2, —
NHC(O)NHR2, —
NHC(O)NR7R8, —
NHC(O)N(R2)2, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, —
SC(R1)2C(O)OH, —
SC(R1)2C(O)OR2, —
SCH2C(O)OH, —
SCF2C(O)OH, —
SO2NH2, —
SO2NHR2, —
SO2N(R2)2, SO2NR7R8, —
SO2NHC(O)R2, —
SR2, —
SO2NHC(O)NHR2, —
SO2NHC(O)N(R2)2, —
SO2NHC(O)NR7R8, cyano, tetrazol-5-yl, carboxy, —
C(O)OR2, —
C(O)NH2, —
C(O)NHR2, —
C(O)N(R2)2, —
C(O)NR7R8, —
C(O)NHC(O)R2, —
C(O)NHC(O)NHR2, —
C(O)NHC(O)N(R2)2, —
C(O)NHC(O)NR7R8, —
C(O)NHSO2R2, —
C(O)NHSO2NHR2, —
C(O)NHSO2N(R2), —
C(O)NHSO2NR7R8, —
C(CH3)2C(O)OH, all of which can be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R2α
and R6α
are independently selected from the group consisting of halogen, nitro, lower alkyl, haloalkyl, aryl, heteroaryl, aminoalkyl, hydroxyalkyl, alkoxy, lower alkoxy, haloalkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, —
OC(R1)2C(O)OH, —
OC(R1)2C(O)OR2, —
OC(R1)2C(O)NH2, —
OC(R1)2C(O)NHR2, —
OC(R1)2C(O)N(R2)2, —
OC(R1)2C(O)NR7R8, —
SC(R1)2C(O)OH, —
SC(R1)2C(O)OR2, —
SCH2C(O)OH, —
SCF2C(O)OH, —
SO2NH2, —
SO2NHR2, —
SO2N(R2)2, SO2NR7R8, —
SO2NHC(O)R2, —
SR2, —
SO2NHC(O)NHR2, —
SO2NHC(O)N(R2)2, —
SO2NHC(O)NR7R8, all of which can be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R1 is independently selected from the group consisting of hydrogen, lower alkyl, carbocycle, cycloalkyl, aryl, heteroaryl, heterocyclic, arylalkyl, heteroarylalkyl, and heterocyclicalkyl, wherein all may be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R2 is independently selected from the group consisting of alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, aryl, heteroaryl, heterocyclic, arylalkyl, heteroarylalkyl, and heterocyclicalkyl, wherein all may be substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R7 and R8 are independently selected from the group consisting of alkyl, alkenyl, heteroaryl and aryl and linked together forming a 4- to 12-membered monocyclic, bicylic, tricyclic or benzofused ring;
wherein one of R2α
, R3α
, R4α
, R5α
or R6α
must be a carbon-carbon linked heteroaryl;
wherein all R1, R2, R7 and R8 substituents can be optionally substituted where possible with one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2.
-
-
8. The compound of claim 5 or its pharmaceutically acceptable salt or ester, wherein:
-
R3α
, R4α
, R5α
, R2β
, R3β
, R4β
, R5β
and R6β
are independently selected from the group consisting of hydrogen, halogen, nitro, alkyl, lower alkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heterocyclic, aminoalkyl, hydroxyl, hydroxyalkyl, alkoxy, lower alkoxy, haloalkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, —
OC(R1)2C(O)OH, —
OC(R1)2C(O)OR2, amino, alkylamino, acylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, heteroarylamino, heteroaralkylamino, heterocyclicamino, heterocyclicalkylamino, —
NHR2, N(R2)2, —
NR7R8, —
NHC(R1)2C(O)OH, —
NHC(R1)2C(O)OR2, —
NHC(O)R2, —
N(R2)C(O)R2—
NHC(O)OR, —
NHC(O)SR2, —
NHSO2NHR2, —
NHSO2R2, —
NHSO2NR7R8, —
N(C(O)NHR2)2, —
NR2SO2R2, —
NHC(O)NHR2, —
NHC(O)NR7R8, —
NHC(O)N(R2)2, —
SC(R1)2C(O)OH, —
SC(R1)2C(O)OR2, —
SO2NH2, —
SO2NHR2, —
SO2N(R2)2, SO2NR7R8, —
SO2NHC(O)R2, —
SR2, —
SO2NHC(O)NHR2, —
SO2NHC(O)N(R2) 2, —
SO2NHC(O)NR7R8, cyano, tetrazol-5-yl, carboxy, —
C(O)OR2, —
C(O)NH2, —
C(O)NHR2, —
C(O)N(R2)2, —
C(O)NR7R8, —
C(O)NHC(O)R2, —
C(O)NHC(O)NHR2, —
C(O)NHC(O)N(R2)2, —
C(O)NHC(O)NR7R8, —
C(O)NHSO2R2, —
C(O)NHSO2NHR2, —
C(O)NHSO2N(R2), —
C(O)NHSO2NR7R8, —
C(CH3)2C(O)OH, all of which can be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R2α
and R6α
are independently selected from the group consisting of halogen, lower alkyl, lower alkoxy, aryl, and heteroaryl;
R1 is independently selected from the group consisting of hydrogen, lower alkyl, carbocycle, cycloalkyl, aryl, heteroaryl, heterocyclic, arylalkyl, heteroarylalkyl, and heterocyclicalkyl, wherein all may be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R2 is independently selected from the group consisting of alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, aryl, heteroaryl, heterocyclic, arylalkyl, heteroarylalkyl, and heterocyclicalkyl, wherein all may be substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R7 and R8 are independently selected from the group consisting of alkyl, alkenyl, heteroaryl and aryl and linked together forming a 4- to 12-membered monocyclic, bicylic, tricyclic or benzofused ring;
wherein one of R2α
, R3α
, R4α
, R5α
or R6α
must be a carbon-carbon linked heteroaryl;
wherein all R1, R2, R7 and R8 substituents can be optionally substituted where possible with one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2.
-
-
9. The compound of claim 5 or its pharmaceutically acceptable salt or ester, wherein:
-
R2β
, R3β
, R4β
, R5β
and R6β
are independently selected from the group consisting of hydrogen, halogen, nitro, lower alkyl, haloalkyl, heteroaryl, heterocyclic, hydroxyl, lower alkoxy, —
OC(R1)2C(O)OH, —
OC(R1)2C(O)OR2, —
SO2NHR2, —
SO2N(R2)2, carboxy, and —
C(O)OR2;
R2α
and R6α
are independently selected from the group consisting of halogen, heteroaryl, aryl, lower alkyl, and lower alkoxy;
R1 is independently selected from the group consisting of hydrogen and lower alkyl;
R2 is lower alkyl, optionally substituted by one or more carboxy groups;
wherein one of R2α
, R3α
, R4α
, R5α
, or R6α
must be a carbon-carbon linked heteroaryl.
-
-
10. The compound of claim 5 or its pharmaceutically acceptable salt or ester, wherein:
-
R2β
, R3β
, R5β
and R6β
are independently selected from the group consisting of hydrogen, nitro, lower alkyl, haloalkyl, heteroaryl, heterocyclic, hydroxyl, lower alkoxy, —
OC(R1)2C(O)OH, —
OC(R1)2C(O)OR2, —
SO2NHR2, —
SO2N(R2)2, carboxy, and —
C(O)OR;
R4β
is independently selected from the group consisting of hydrogen, halogen, nitro, lower alkyl, haloalkyl, heteroaryl, heterocyclic, hydroxyl, lower alkoxy, —
OC(R1)2C(O)OH, —
OC(R1)2C(O)OR2, —
SO2NHR2, —
SO2N(R2)2, carboxy, and C(O)OR2;
R2α
and R6α
are independently selected from the group consisting of halogen, heteroaryl, aryl, lower alkyl, and lower alkoxy;
R1 is independently selected from the group consisting of hydrogen and lower alkyl;
R2 is lower alkyl, optionally substituted by one or more carboxy groups;
wherein one of R2α
, R3α
, R4α
, R5α
, or R6α
must be a carbon-carbon linked heteroaryl.
-
-
11. The compound of claim 5 or its pharmaceutically acceptable salt or ester, wherein:
-
R2β
, R3β
, R4β
, R5β
and R6β
are independently selected from the group consisting of hydrogen, chloro, fluoro, bromo, nitro, methyl, tert-butyl, trifluoromethyl, thienyl, benzothienyl, methoxypyridyl, pyridyl, hydroxyl, methoxy, carboxy, —
OCH2C(O)OH, —
OC(CH3)2C(O)OH, and —
SO2N(CH3)CH2C(O)OH;
R2α
and R6α
are independently selected from the group consisting of chloro, fluoro, bromo, nitro, methyl, and methoxy;
wherein one of R2α
, R3α
, R4α
, R5α
, or R6α
must be thienyl, benzothienyl, methoxypyridyl, or pyridyl.
-
-
12. The compound of claim 1 selected from the group consisting of:
-
4-[1-(2,6-Dimethoxy-3-thien-2-yl-benzoyl)-vinyl]-benzoic acid;
1-(2,6-Dimethoxy-3-thien-2-yl-phenyl)-2-(2-methoxy-phenyl)-propenone;
2-(3,5-Di-tert-butyl-4-hydroxy-phenyl)-1-(2,6-dimethoxy-3-thien-2-yl-phenyl)-propenone;
2-{4-[1-(2,6-Dimethoxy-3-thien-2-yl-benzoyl)-vinyl]-phenoxy}-2-methyl-propionic acid;
1-(2,6-Dimethoxy-3-thien-2-yl-phenyl)-2-(4-trifluoromethyl-phenyl)-propenone;
1-(2,6-Dimethoxy-3-thien-2-yl-phenyl)-2-(4-nitro-phenyl)-propenone;
2-(2,6-Dichloro-phenyl)-1-(2,6-dimethoxy-3-thien-2-yl-phenyl)-propenone;
2-{3-[1-(2,6-Dimethoxy-3-thien-2-yl-benzoyl)-vinyl]-phenoxy}-2-methyl-propionic acid;
2-{3-[1-(3-Benzo[b]thien-2-yl-2,6-dimethoxy-benzoyl)-vinyl]-phenoxy}-2-methyl-propionic acid;
({4-[1-(2,6-Dimethoxy-3-thien-2-yl-benzoyl)-vinyl]-benzenesulfonyl}-methyl-amino)-acetic acid; and
1-(2,6-Dimethoxy-3-thien-2-yl-phenyl)-2-(2-fluoro-6-trifluoromethyl-phenyl)-propenone.
-
-
13. The compound of claim 4 or its pharmaceutically acceptable salt or ester, wherein:
-
R3α
, R4α
, R5α
, R2β
, R3β
, R4β
, R5β
and R6β
are independently selected from the group consisting of hydrogen, halogen, nitro, alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, cycloalkylalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heteroaryl lower alkyl, heterocyclic, heterocyclic lower alkyl, alkylthioalkyl, cycloalkylthioalkyl, arylthio lower alkyl, aralkyl lower thioalkyl, heteroarylthio lower alkyl, heteroaralkyl lower thioalkyl, heterocyclicthio lower alkyl, heterocyclicalkyl lower thioalkyl, —
C(O)R2, R2C(O)alkyl, aminoalkyl, cycloalkylaminoalkyl, arylamino lower alkyl, heteroarylamino lower alkyl, heterocyclicamino lower alkyl, hydroxyl, hydroxyalkyl, alkoxy, lower alkoxy, —
(O(CH2)2)1-3—
O-lower alkyl, cycloalkyloxy, cycloalkylalkoxy, haloalkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, heteroaryl lower alkoxy, heterocyclicoxy, heterocyclicalkoxy, heterocyclic lower alkoxy, —
OC(R1)2C(O)OH, —
OC(R1)2C(O)OR2, —
OC(R1)2C(O)NH2, —
OC(R1)2C(O)NHR2, —
OC(R1)2C(O)N(R2)2, —
OC(R1)2C(O)NR7R8, amino, alkylamino, acylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, heteroarylamino, heteroaralkylamino, heterocyclicamino, heterocyclicalkylamino, —
NHR2, N(R2)2, —
NR7R8, —
NHC(R1)2C(O)OH, —
NHC(R1)2C(O)OR2, —
NHC(O)R2, —
N(R2)C(O)R2, —
NHC(O)OR2, —
NHC(O)SR2, —
NHSO2NHR2, —
NHSO2R2, —
NHSO2NR7R8, —
N(C(O)NHR2)2, —
NR2SO2R2, —
NHC(O)NHR2, —
NHC(O)NR7R8, —
NHC(O)N(R2)2, thiol, alkylthio, cycloalkylthio, cycloalkylalkylthio, haloalkylthio, arylthio, aralkylthio, heteroarylthio, heteroaralkylthio, heterocyclicthio, heterocyclicalkylthio, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, —
SC(R1)2C(O)OH, —
SC(R1)2C(O)OR2, —
SCH2C(O)OH, —
SCF2C(O)OH, —
SO2NH2, —
SO2NHR2, —
SO2N(R2)2, SO2NR7R8, —
SO2NHC(O)R2, —
SR2, —
SO2NHC(O)NHR2, —
SO2NHC(O)N(R2)2, —
SO2NHC(O)NR7R8, sulfonic acid, sulfonate, sulfate, sulfinic acid, sulfenic acid, cyano, tetrazol-5-yl, carboxy, —
C(O)OR2, —
C(O)NH2, —
C(O)NHR2, —
C(O)N(R2)2, —
C(O)NR7R8, —
C(O)NHC(O)R2, —
C(O)NHC(O)NHR2, —
C(O)NHC(O)N(R2)2, —
C(O)NHC(O)NR7R8, —
C(O)NHSO2R2, —
C(O)NHSO2NHR2, —
C(O)NHSO2N(R2), —
C(O)NHSO2NR7R8, —
C(CH3)2C(O)OH, —
(CH2)yC(O)OH, wherein y is 1, 2, 3, 4, 5, or 6, —
PO2H2, —
PO3H2, —
P(R2)O2H, and phosphate, all of which can be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)N7R8, and —
C(O)N(R2)2;
R2α
and R6α
are independently selected from the group consisting of halogen, nitro, alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heteroaryl lower alkyl, heterocyclic, heterocyclic lower alkyl, R2C(O) alkyl, aminoalkyl, cycloalkylaminoalkyl, arylamino lower alkyl, heteroarylamino lower alkyl, heterocyclicamino lower alkyl, hydroxyalkyl, alkoxy, lower alkoxy, cycloalkyloxy, cycloalkylalkoxy, haloalkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, heteroaryl lower alkoxy, heterocyclicoxy, heterocyclicalkoxy, heterocyclic lower alkoxy, —
OC(R)2C(O)OH, —
OC(R1)2C(O)OR2, —
OC(R1)2C(O)NH2, —
OC(R1)2C(O)NHR2, —
OC(R1)2C(O)N(R2)2, —
OC(R1)2C(O)NR7R8, —
NHSO2NHR2, —
NHSO2R2, —
NHSO2NR7R8, —
NR2SO2R2, alkylthio, cycloalkylthio, —
SC(R1)2C(O)OH, —
SC(R1)2C(O)OR2, —
SCH2C(O)OH, —
SCF2C(O)OH, —
SO2NH2, —
SO2NHR2, —
SO2N(R2)2, SO2NR7R8, —
SO2NHC(O)R2, —
SR2, —
SO2NHC(O)NHR2, —
SO2NHC(O)N(R2) 2, —
SO2NHC(O)NR7R8, cyano, tetrazol-5-yl, carboxy, —
C(O)OR2, —
C(O)NH2, —
C(O)NHR2, —
C(O)N(R2)2, —
C(O)NR7R8, C(O)NHC(O)R2, —
C(O)NHC(O)NHR2, —
C(O)NHC(O)N(R2)2, —
C(O)NHC(O)NR7R8, —
C(O)NHSO2R2, —
C(O)NHSO2NHR2, —
C(O)NHSO2N(R2), —
C(O)NHSO2NR7R8, —
C(CH3)2C(O)OH, —
(CH2)yC(O)OH, wherein y is 1, 2, 3, 4, 5, or 6, all of which can be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)N7R8, and —
C(O)N(R2)2;
R1 is independently selected from the group consisting of hydrogen, lower alkyl, carbocycle, cycloalkyl, aryl, heteroaryl, heterocyclic, arylalkyl, heteroarylalkyl, and heterocyclicalkyl, wherein all may be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R2 is independently selected from the group consisting of alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, aryl, heteroaryl, heterocyclic, arylalkyl, heteroarylalkyl, and heterocyclicalkyl, wherein all may be substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R7 and R8 are independently selected from the group consisting of alkyl, alkenyl, heteroaryl and aryl and linked together forming a 4- to 12-membered monocyclic, bicylic, tricyclic or benzofused ring;
wherein one of R2β
, R3β
, R4β
, R5β
or R6β
must be a carbon-carbon linked heteroaryl;
wherein all R1, R2, R7 and R8 substituents can be optionally substituted where possible with one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2.
-
-
14. The compound of claim 13 or its pharmaceutically acceptable salt or ester, wherein:
-
R3α
, R4α
, R5α
, R2β
, R3β
, R4β
, R5β
and R6β
are independently selected from the group consisting of hydrogen, halogen, nitro, alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, cycloalkylalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heteroaryl lower alkyl, heterocyclic, heterocyclic lower alkyl, R2C(O)alkyl, aminoalkyl, hydroxyl, hydroxyalkyl, alkoxy, lower alkoxy, cycloalkyloxy, haloalkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, —
OC(R1)2C(O)OH, —
OC(R1)2C(O)OR2, —
OC(R1)2C(O)NH2, —
OC(R1)2C(O)NHR2, —
OC(R1)2C(O)N(R2)2, —
OC(R1)2C(O)NR7R8, amino, alkylamino, acylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, heteroarylamino, heteroaralkylamino, heterocyclicamino, heterocyclicalkylamino, —
NHR2, N(R2)2, —
NR7R8, —
NHC(R1)2C(O)OH, —
NHC(R1)2C(O)OR2, —
NHC(O)R2, —
N(R2)C(O)R2, —
NHC(O)OR2, —
NHC(O)SR2, —
NHSO2NHR2, —
NHSO2R2, —
NHSO2NR7R8, —
N(C(O)NHR2)2, —
NR2SO2R2, —
NHC(O)NHR2, —
NHC(O)NR7R8, —
NHC(O)N(R2)2, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, —
SC(R1)2C(O)OH, —
SC(R1)2C(O)OR2, —
SCH2C(O)OH, —
SCF2C(O)OH, —
SO2NH2, —
SO2NHR2, —
SO2N(R2)2, SO2NR7R8, —
SO2NHC(O)R2, —
SR2, —
SO2NHC(O)NHR2, —
SO2NHC(O)N(R2) 2, —
SO2NHC(O)NR7R8, cyano, tetrazol-5-yl, carboxy, —
C(O)OR2, —
C(O)NH2, —
C(O)NHR2, —
C(O)N(R2)2, —
C(O)NR7R8, —
C(O)NHC(O)R2, —
C(O)NHC(O)NHR2, —
C(O)NHC(O)N(R2)2, —
C(O)NHC(O)NR7R8, —
C(O)NHSO2R2, —
C(O)NHSO2NHR2, —
C(O)NHSO2N(R2), —
C(O)NHSO2NR7R8, —
C(CH3)2C(O)OH, all of which can be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R2α
and R6α
are independently selected from the group consisting of halogen, nitro, alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heteroaryl lower alkyl, heterocyclic, heterocyclic lower alkyl, R2C(O)alkyl, aminoalkyl, hydroxyalkyl, alkoxy, lower alkoxy, cycloalkyloxy, cycloalkylalkoxy, haloalkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, heteroaryl lower alkoxy, heterocyclicoxy, heterocyclicalkoxy, heterocyclic lower alkoxy, —
OC(R1)2C(O)OH, —
OC(R1)2C(O)OR2, —
OC(R1)2C(O)NH2, —
OC(R1)2C(O)NHR2, —
OC(R1)2C(O)N(R2)2, —
OC(R1)2C(O)NR7R8, —
SC(R)2C(O)OH, —
SC(R1)2C(O)OR2, —
SCH2C(O)OH, —
SCF2C(O)OH, —
SO2NH2, —
SO2NHR2, —
SO2N(R2)2, SO2NR7R8, —
SO2NHC(O)R2, —
SR2, —
SO2NHC(O)NHR2, —
SO2NHC(O)N(R2) 2, —
SO2NHC(O)NR7R8, all of which can be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R1 is independently selected from the group consisting of hydrogen, lower alkyl, carbocycle, cycloalkyl, aryl, heteroaryl, heterocyclic, arylalkyl, heteroarylalkyl, and heterocyclicalkyl, wherein all may be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R2 is independently selected from the group consisting of alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, aryl, heteroaryl, heterocyclic, arylalkyl, heteroarylalkyl, and heterocyclicalkyl, wherein all may be substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R7 and R8 are independently selected from the group consisting of alkyl, alkenyl, heteroaryl and aryl and linked together forming a 4- to 12-membered monocyclic, bicylic, tricyclic or benzofused ring;
wherein one of R2β
, R3β
, R4β
, R5β
or R6β
must be a carbon-carbon linked heteroaryl;
wherein all R1, R2, R7 and R8 substituents can be optionally substituted where possible with one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2.
-
-
15. The compound of claim 14 or its pharmaceutically acceptable salt or ester, wherein:
-
R3α
, R4α
, R5α
, R2β
, R3β
, R4β
, R5β
and R6β
are independently selected from the group consisting of hydrogen, halogen, nitro, alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, cycloalkylalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heteroaryl lower alkyl, heterocyclic, heterocyclic lower alkyl, R2C(O)alkyl, aminoalkyl, hydroxyl, hydroxyalkyl, alkoxy, lower alkoxy, cycloalkyloxy, haloalkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, —
OC(R1)2C(O)OH, —
OC(R1)2C(O)OR2, —
OC(R1)2C(O)NH2, —
OC(R1)2C(O)NHR2, —
OC(R1)2C(O)N(R2)2, —
OC(R1)2C(O)NR7R8, amino, alkylamino, acylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, heteroarylamino, heteroaralkylamino, heterocyclicamino, heterocyclicalkylamino, —
NHR, N(R2)2, —
NR7R8, —
NHC(R1)2C(O)OH, —
NHC(R1)2C(O)OR2, —
NHC(O)R2, —
N(R2)C(O)R2, —
NHC(O)OR2, —
NHC(O)SR2, —
NHSO2NHR2, —
NHSO2R2, —
NHSO2NR7R8, —
N(C(O)NHR2)2, —
NR2SO2R2, —
NHC(O)NHR2, —
NHC(O)NR7R8, —
NHC(O)N(R2)2, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, —
SC(R1)2C(O)OH, —
SC(R1)2C(O)OR2, —
SCH2C(O)OH, —
SCF2C(O)OH, —
SO2NH2, —
SO2NHR2, —
SO2N(R2)2, SO2NR7R8, —
SO2NHC(O)R2, —
SR2, —
SO2NHC(O)NHR2, —
SO2NHC(O)N(R2) 2, —
SO2NHC(O)NR7R8, cyano, tetrazol-5-yl, carboxy, —
C(O)OR2, —
C(O)NH2, —
C(O)NHR2, —
C(O)N(R2)2, —
C(O)NR7R7, —
C(O)NHC(O)R2, —
C(O)NHC(O)NHR2, —
C(O)NHC(O)N(R2)2, —
C(O)NHC(O)NR7R8, —
C(O)NHSO2R2, —
C(O)NHSO2NHR2, —
C(O)NHSO2N(R2), —
C(O)NHSO2NR7R8, —
C(CH3)2C(O)OH, all of which can be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R2α
and R6α
are independently selected from the group consisting of halogen, nitro, lower alkyl, haloalkyl, aryl, heteroaryl, aminoalkyl, hydroxyalkyl, alkoxy, lower alkoxy, haloalkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, —
OC(R1)2C(O)OH, —
OC(R1)2C(O)OR2, —
OC(R1)2C(O)NH2, —
OC(R1)2C(O)NHR2, —
OC(R1)2C(O)N(R2)2, —
OC(R1)2C(O)NR7R8, —
SC(R1)2C(O)OH, —
SC(R1)2C(O)OR2, —
SCH2C(O)OH, —
SCF2C(O)OH, —
SO2NH2, —
SO2NHR2, —
SO2N(R2)2, SO2NR7R8, —
SO2NHC(O)R2, —
SR2, —
SO2NHC(O)NHR2, —
SO2NHC(O)N(R2) 2, —
SO2NHC(O)NR7R8, all of which can be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R1 is independently selected from the group consisting of hydrogen, lower alkyl, carbocycle, cycloalkyl, aryl, heteroaryl, heterocyclic, arylalkyl, heteroarylalkyl, and heterocyclicalkyl, wherein all may be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R2 is independently selected from the group consisting of alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, aryl, heteroaryl, heterocyclic, arylalkyl, heteroarylalkyl, and heterocyclicalkyl, wherein all may be substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R7 and R8 are independently selected from the group consisting of alkyl, alkenyl, heteroaryl and aryl and linked together forming a 4- to 12-membered monocyclic, bicylic, tricyclic or benzofused ring;
wherein one of R2β
, R3β
, R4β
, R5β
or R6β
must be a carbon-carbon linked heteroaryl;
wherein all R1, R2, R7 and R8 substituents can be optionally substituted where possible with one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2.
-
-
16. The compound of claim 13 or its pharmaceutically acceptable salt or ester, wherein:
-
R3α
, R4α
, R5α
, R2β
, R3β
, R4β
, R5β
and R6β
are independently selected from the group consisting of hydrogen, halogen, nitro, alkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heterocyclic, aminoalkyl, hydroxyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, —
OC(R1)2C(O)OH, —
OC(R1)2C(O)OR2, amino, alkylamino, acylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, heteroarylamino, heteroaralkylamino, heterocyclicamino, heterocyclicalkylamino, —
NHR2, N(R2)2, —
NR7R8, —
NHC(R1)2C(O)OH, —
NHC(R1)2C(O)OR2, —
NHC(O)R2, —
N(R2)C(O)R2, —
NHC(O)OR2, —
NHC(O)SR2, —
NHSO2NHR2, —
NHSO2R2, —
NHSO2NR7R8, —
N(C(O)NHR2)2, —
NR2SO2R2, —
NHC(O)NHR2, —
NHC(O)NR7R8, —
NHC(O)N(R2)2, —
SC(R1)2C(O)OH, —
SC(R1)2C(O)OR2, —
SO2NH2, —
SO2NHR2, —
SO2N(R2)2, SO2NR7R8, —
SO2NHC(O)R2, —
SR2, —
SO2NHC(O)NHR2, —
SO2NHC(O)N(R2) 2, —
SO2NHC(O)NR7R8, cyano, tetrazol-5-yl, carboxy, —
C(O)OR2, —
C(O)NH2, —
C(O)NHR2, —
C(O)N(R2)2, —
C(O)NR7R8, —
C(O)NHC(O)R2, —
C(O)NHC(O)NHR2, —
C(O)NHC(O)N(R2)2, —
C(O)NHC(O)NR7R8, —
C(O)NHSO2R2, —
C(O)NHSO2NHR2, —
C(O)NHSO2N(R2), —
C(O)NHSO2NR7R8, —
C(CH3)2C(O)OH, all of which can be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R2α
and R6α
are independently selected from the group consisting of F, Cl, Br, —
CH3, —
OCH3, aryl, and heteroaryl;
R1 is independently selected from the group consisting of hydrogen, lower alkyl, carbocycle, cycloalkyl, aryl, heteroaryl, heterocyclic, arylalkyl, heteroarylalkyl, and heterocyclicalkyl, wherein all may be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R1 is independently selected from the group consisting of alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, aryl, heteroaryl, heterocyclic, arylalkyl, heteroarylalkyl, and heterocyclicalkyl, wherein all may be substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R7 and R8 are independently selected from the group consisting of alkyl, alkenyl, heteroaryl and aryl and linked together forming a 4- to 12-membered monocyclic, bicylic, tricyclic or benzofused ring;
wherein one of R2β
, R3β
, R4β
, R5β
or R6β
must be a carbon-carbon linked heteroaryl;
wherein all R1, R2, R7 and R8 substituents can be optionally substituted where possible with one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2.
-
-
17. The compound of claim 13 or its pharmaceutically acceptable salt or ester, wherein:
-
R2β
, R3β
, R4β
, R5β
and R6β
are independently selected from the group consisting of hydrogen, halogen, lower alkyl, haloalkyl, heteroaryl, heterocyclic, lower alkoxy, —
OC(R1)2C(O)OH, —
OC(R1)2C(O)OR2, —
SO2NHR2, —
SO2N(R2)2, carboxy, and C(O)OR2;
R2α
and R6α
are independently selected from the group consisting of halogen, aryl, heteroaryl, lower alkyl, and lower alkoxy;
R1 is independently selected from the group consisting of hydrogen and lower alkyl;
R2 is lower alkyl, optionally substituted by one or more carboxy groups;
wherein one of R2β
, R3β
, R4β
, R5β
or R6β
must be a carbon-carbon linked heteroaryl.
-
-
18. The compound of claim 13 or its pharmaceutically acceptable salt or ester, wherein:
-
R2β
, R3β
, R4β
, R5β
and R6β
are independently selected from the group consisting of hydrogen, lower alkyl, haloalkyl, heteroaryl, heterocyclic, lower alkoxy, OC(R1)2C(O)OH, —
OC(R1)2C(O)OR2, —
SO2NHR2, —
SO2N(R2)2, carboxy, and —
C(O)OR2;
R4β
is selected from the group consisting of hydrogen, halogen, lower alkyl, haloalkyl, heteroaryl, heterocyclic, lower alkoxy, —
OC(R1)2C(O)OH, —
OC(R1)2C(O)OR2, —
SO2NHR2, —
SO2N(R2)2, carboxy, and —
C(O)OR2;
R2β
and R6α
are independently selected from the group consisting of halogen, aryl, heteroaryl, lower alkyl, and lower alkoxy;
R1 is independently selected from the group consisting of hydrogen and lower alkyl;
R2 is lower alkyl, optionally substituted by one or more carboxy groups;
wherein one of R2β
, R3β
, R4β
, R5β
or R6β
must be a carbon-carbon linked heteroaryl.
-
-
19. The compound of claim 13 or its pharmaceutically acceptable salt or ester, wherein:
-
R2β
, R3β
, R4β
, R5β
and R6β
are independently selected from the group consisting of hydrogen, chloro, fluoro, bromo, nitro, methyl, tert-butyl, trifluoromethyl, thienyl, benzothienyl, methoxypyridyl, pyridyl, hydroxyl, methoxy, carboxy, —
OCH2C(O)OH, —
OC(CH3)2C(O)OH, and —
SO2N(CH3)CH2C(O)OH;
R2α
and R6α
are independently selected from the group consisting of chloro, fluoro, bromo, nitro, methyl, and methoxy;
wherein one of R2β
, R3β
, R4β
, R5β
or R6β
must be thienyl, benzothienyl, methoxypyridyl, or pyridyl.
-
-
20. The compound of claim 1 selected from the group consisting of:
-
1-(2,6-Dichloro-phenyl)-2-(2-methoxy-5-thien-2-yl-phenyl)-propenone;
1-(2,6-Dimethyl-phenyl)-2-(2-methoxy-5-thien-2-yl-phenyl)-propenone;
4-[1-(2-Chloro-6-methyl-benzoyl)-vinyl]-3-thien-2-yl-benzoic acid;
4-[1-(2,6-Dimethyl-benzoyl)-vinyl]-3-thien-2-yl-benzoic acid;
4-[1-(2,6-Dimethoxy-benzoyl)-vinyl]-3-thien-2-yl-benzoic acid;
2-{4-[1-(2,6-Dimethoxy-benzoyl)-vinyl]-2-thien-2-yl-phenoxy}-2-methyl-propionic acid;
1-(2,6-Dimethyl-phenyl)-2-(2-thien-2-yl-phenyl)-propenone;
1-(2,6-Dimethyl-phenyl)-2-[2-(2-methoxy-pyridin-3-yl)-phenyl]-propenone;
1-(2,6-Dimethoxy-phenyl)-2-(2-thien-2-yl-phenyl)-propenone;
1-(2,6-Dimethoxy-phenyl)-2-(2-methoxy-5-thien-2-yl-phenyl)-propenone; and
2-{2-[1-(2,6-Dimethoxy-benzoyl)-vinyl]-4-thien-2-yl-phenoxy}-2-methyl-propionic acid.
-
-
21. The compound of claim 1 or its pharmaceutically acceptable salt or ester, wherein:
-
R2α
, R3α
, R4α
, R5α
, R6α
, and R4β
are independently selected from the group consisting of hydrogen, halogen, nitro, alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, cycloalkylalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heteroaryl lower alkyl, heterocyclic, heterocyclic lower alkyl, alkylthioalkyl, cycloalkylthioalkyl, arylthio lower alkyl, aralkyl lower thioalkyl, heteroarylthio lower alkyl, heteroaralkyl lower thioalkyl, heterocyclicthio lower alkyl, heterocyclicalkyl lower thioalkyl, —
C(O)R2, R2C(O)alkyl, aminoalkyl, cycloalkylaminoalkyl, arylamino lower alkyl, heteroarylamino lower alkyl, heterocyclicamino lower alkyl, hydroxyl, hydroxyalkyl, alkoxy, lower alkoxy, —
(O(CH2)2)1-3—
O-lower alkyl, cycloalkyloxy, cycloalkylalkoxy, haloalkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, heteroaryl lower alkoxy, heterocyclicoxy, heterocyclicalkoxy, heterocyclic lower alkoxy, —
OC(R1)2C(O)OH, —
OC(R1)2C(O)OR2, —
OC(R1)2C(O)NH2, —
OC(R1)2C(O)NHR2, —
OC(R1)2C(O)N(R2)2, —
OC(R1)2C(O)NR7R8, amino, alkylamino, acylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, heteroarylamino, heteroaralkylamino, heterocyclicamino, heterocyclicalkylamino, —
NHR2, N(R2)2, —
NR7R8, —
NHC(R1)2C(O)OH, —
NHC(R1)2C(O)OR2, —
NHC(O)R2, —
N(R2)C(O)R2, —
NHC(O)OR2, —
NHC(O)SR2, —
NHSO2NHR2, —
NHSO2R2, —
NHSO2NR7R8, —
N(C(O)NHR2)2, —
NR2SO2R2, —
NHC(O)NHR2, —
NHC(O)NR7R8, —
NHC(O)N(R2)2, thiol, alkylthio, cycloalkylthio, cycloalkylalkylthio, haloalkylthio, arylthio, aralkylthio, heteroarylthio, heteroaralkylthio, heterocyclicthio, heterocyclicalkylthio, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, —
SC(R1)2C(O)OH, —
SC(R1)2C(O)OR2, —
SCH2C(O)OH, —
SCF2C(O)OH, —
SO2NH2, —
SO2NHR2, —
SO2N(R2)2, SO2NR7R8, —
SO2NHC(O)R2, —
SR2, —
SO2NHC(O)NHR2, —
SO2NHC(O)N(R2)2, —
SO2NHC(O)NR7R8, sulfonic acid, sulfonate, sulfate, sulfinic acid, sulfenic acid, cyano, tetrazol-5-yl, carboxy, —
C(O)OR2, —
C(O)NH2, —
C(O)NHR2, —
C(O)N(R2)2, —
C(O)NR7R8, —
C(O)NHC(O)R2, —
C(O)NHC(O)NHR2, —
C(O)NHC(O)N(R2)2, —
C(O)NHC(O)NR7R8, —
C(O)NHSO2R2, —
C(O)NHSO2NHR2, —
C(O)NHSO2N(R2), —
C(O)NHSO2NR7R8, —
C(CH3)2C(O)OH, —
(CH2)yC(O)OH, wherein y is 1, 2, 3, 4, 5, or 6, —
PO2H2, —
PO3H2, —
P(R2)O2H, and phosphate, all of which can be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R2β
, R3β
, R5β
and R6β
are independently selected from the group consisting of hydrogen, nitro, alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, cycloalkylalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heteroaryl lower alkyl, heterocyclic, heterocyclic lower alkyl, alkylthioalkyl, cycloalkylthioalkyl, arylthio lower alkyl, aralkyl lower thioalkyl, heteroarylthio lower alkyl, heteroaralkyl lower thioalkyl, heterocyclicthio lower alkyl, heterocyclicalkyl lower thioalkyl, —
C(O)R2, R2C(O)alkyl, aminoalkyl, cycloalkylaminoalkyl, arylamino lower alkyl, heteroarylamino lower alkyl, heterocyclicamino lower alkyl, hydroxyl, hydroxyalkyl, alkoxy, lower alkoxy, —
(O(CH2)2)1-3—
O-lower alkyl, cycloalkyloxy, cycloalkylalkoxy, haloalkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, heteroaryl lower alkoxy, heterocyclicoxy, heterocyclicalkoxy, heterocyclic lower alkoxy, —
OC(R1)2C(O)OH, —
OC(R1)2C(O)OR2, —
OC(R1)2C(O)NH2, —
OC(R1)2C(O)NHR2, —
OC(R1)2C(O)N(R2)2, —
OC(R1)2C(O)NR7R8, amino, alkylamino, acylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, heteroarylamino, heteroaralkylamino, heterocyclicamino, heterocyclicalkylamino, —
NHR2, N(R2)2, —
NR7R8, —
NHC(R1)2C(O)OH, —
NHC(R1)2C(O)OR2, —
NHC(O)R2, —
N(R2)C(O)R2, —
NHC(O)OR2, —
NHC(O)SR2, —
NHSO2NHR2, —
NHSO2R2, —
NHSO2NR7R8, —
N(C(O)NHR2)2, —
NR2SO2R2, —
NHC(O)NHR2, —
NHC(O)NR7R8, —
NHC(O)N(R2)2, thiol, alkylthio, cycloalkylthio, cycloalkylalkylthio, haloalkylthio, arylthio, aralkylthio, heteroarylthio, heteroaralkylthio, heterocyclicthio, heterocyclicalkylthio, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, —
SC(R1)2C(O)OH, —
SC(R1)2C(O)OR2, —
SCH2C(O)OH, —
SCF2C(O)OH, —
SO2NH2, —
SO2NHR2, —
SO2N(R2)2, SO2NR7R8, —
SO2NHC(O)R2, —
SR2, —
SO2NHC(O)NHR2, —
SO2NHC(O)N(R2) 2, —
SO2NHC(O)NR7R8, sulfonic acid, sulfonate, sulfate, sulfinic acid, sulfenic acid, cyano, tetrazol-5-yl, carboxy, —
C(O)OR2, —
C(O)NH2, —
C(O)NHR2, —
C(O)N(R2)2, —
C(O)NR7R8, —
C(O)NHC(O)R2, —
C(O)NHC(O)NHR2, —
C(O)NHC(O)N(R2)2, —
C(O)NHC(O)NR7R8, —
C(O)NHSO2R2, —
C(O)NHSO2NHR2, —
C(O)NHSO2N(R2), —
C(O)NHSO2NR7R8, —
C(CH3)2C(O)OH, —
(CH2)yC(O)OH, wherein y is 1, 2, 3, 4, 5, or 6, —
PO2H2, —
PO3H2, —
P(R2)O2H, and phosphate, all of which can be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R1 is independently selected from the group consisting of hydrogen, lower alkyl, carbocycle, cycloalkyl, aryl, heteroaryl, heterocyclic, arylalkyl, heteroarylalkyl, and heterocyclicalkyl, wherein all may be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R2 is independently selected from the group consisting of alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, aryl, heteroaryl, heterocyclic, arylalkyl, heteroarylalkyl, and heterocyclicalkyl, wherein all may be substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R7 and R8 are independently selected from the group consisting of alkyl, alkenyl, heteroaryl and aryl and linked together forming a 4- to 12-membered monocyclic, bicylic, tricyclic or benzofused ring;
wherein one of R2α
, R3α
, R4α
, R5α
or R6α
must be a carbon-carbon linked heteroaryl;
wherein all R1, R2, R7 and R8 substituents can be optionally substituted where possible with one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2.
-
-
22. The compound of claim 21 or its pharmaceutically acceptable salt or ester, wherein:
-
R2α
, R3α
, R4α
, R5α
, R6α
and R4β
, are independently selected from the group consisting of hydrogen, halogen, nitro, alkyl, haloalkyl, heteroaryl, heterocyclic, hydroxyl, alkoxy, haloalkoxy, heteroaryloxy, heteroarylalkoxy, heterocyclicoxy, heterocyclicalkoxy, —
OC(R1)2C(O)OH, —
OC(R1)2C(O)OR2, —
OC(R1)2C(O)NH2, —
OC(R1)2C(O)NHR2, —
OC(R1)2C(O)N(R2)2, —
OC(R1)2C(O)NR7R8, heteroarylamino, heterocyclicamino, —
NHR2, N(R2)2, —
NR7R8, —
NHC(O)R2, —
N(R2)C(O)R2, —
NHC(O)OR2, —
NHSO2R2, —
NR2SO2R2, cyano, tetrazol-5-yl, carboxy, —
C(O)OR2, —
C(O)NH2, —
C(O)NHR2, —
C(O)N(R2)2, —
C(O)NR7R8, all of which can be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R2β
, R3β
, R5β
and R6β
are independently selected from the group consisting of hydrogen, heteroaryl, heterocyclic, alkyl, alkoxy, and lower alkoxy, all of which can be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R1 is independently selected from the group consisting of hydrogen, and lower alkyl, optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R1 is independently selected from the group consisting of alkyl and lower alkyl, optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R7 and R8 are independently selected from the group consisting of alkyl, alkenyl, heteroaryl and aryl and linked together forming a 4- to 12-membered monocyclic, bicylic, tricyclic or benzofused ring, optionally substituted where possible with one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
wherein one of R2α
, R3α
, R4α
, R5α
or R6α
must be a carbon-carbon linked heteroaryl.
-
-
23. The compound of claim 1 selected from the group consisting of:
-
4-[1-(5-Benzo[b]thien-2-yl-2,4-dimethoxy-benzoyl)-vinyl]-benzoic acid methyl ester;
4-[1-(4-Methoxy-3-thien-2-yl-benzoyl)-vinyl]-benzoic acid;
4-[1-(3,4-Dimethoxy-5-thien-2-yl-benzoyl)-vinyl]-benzoic acid;
1-(5-Benzo[b]thien-2-yl-2,4-dimethoxy-phenyl)-2-(4-methoxy-phenyl)-propenone;
1-(5-Benzo[b]thien-2-yl-2,4-dimethoxy-phenyl)-2-(4-fluoro-phenyl)-propenone;
1-(2-Methoxy-5-thien-2-yl-phenyl)-2-(4-nitro-phenyl)-propenone;
4-[1-(2-Methoxy-5-thien-2-yl-benzoyl)-vinyl]-benzonitrile; and
4-[1-(2-Methoxy-5-thien-2-yl-benzoyl)-vinyl]-benzoic acid.
-
-
24. The compound of claim 1 or its pharmaceutically acceptable salt or ester, wherein:
-
R2α
, R3α
, R4α
, R5α
, R6α
, and R4β
are independently selected from the group consisting of hydrogen, halogen, nitro, alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, cycloalkylalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heteroaryl lower alkyl, heterocyclic, heterocyclic lower alkyl, alkylthioalkyl, cycloalkylthioalkyl, arylthio lower alkyl, aralkyl lower thioalkyl, heteroarylthio lower alkyl, heteroaralkyl lower thioalkyl, heterocyclicthio lower alkyl, heterocyclicalkyl lower thioalkyl, —
C(O)R2, R2C(O)alkyl, aminoalkyl, cycloalkylaminoalkyl, arylamino lower alkyl, heteroarylamino lower alkyl, heterocyclicamino lower alkyl, hydroxyl, hydroxyalkyl, alkoxy, lower alkoxy, —
(O(CH2)2)1-3—
O-lower alkyl, cycloalkyloxy, cycloalkylalkoxy, haloalkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, heteroaryl lower alkoxy, heterocyclicoxy, heterocyclicalkoxy, heterocyclic lower alkoxy, —
OC(R1)2C(O)OH, —
OC(R1)2C(O)OR2, —
OC(R1)2C(O)NH2, —
OC(R1)2C(O)NHR2, —
OC(R2)2C(O)N(R2)2, —
OC(R1)2C(O)NR7R8, amino, alkylamino, acylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, heteroarylamino, heteroaralkylamino, heterocyclicamino, heterocyclicalkylamino, —
NHR2, N(R2)2, —
NR7R8, —
NHC(R1)2C(O)OH, —
NHC(R1)2C(O)OR2, —
NHC(O)R2, —
N(R2)C(O)R2, —
NHC(O)OR2, —
NHC(O)SR2, —
NHSO2NHR2, —
NHSO2R2, —
NHSO2NR7R8, —
N(C(O)NHR2)2, —
NR2SO2R2, —
NHC(O)NHR2, —
NHC(O)NR7R8, —
NHC(O)N(R2)2, thiol, alkylthio, cycloalkylthio, cycloalkylalkylthio, haloalkylthio, arylthio, aralkylthio, heteroarylthio, heteroaralkylthio, heterocyclicthio, heterocyclicalkylthio, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, —
SC(R1)2C(O)OH, —
SC(R1)2C(O)OR2, —
SCH2C(O)OH, —
SCF2C(O)OH, —
SO2NH2, SO2NHR2, —
SO2N(R2)2, SO2NR7R8, —
SO2NHC(O)R2, —
SR2, —
SO2NHC(O)NHR2, SO2NHC(O)N(R2) 2, —
SO2NHC(O)NR7R8, sulfonic acid, sulfonate, sulfate, sulfinic acid, sulfenic acid, cyano, tetrazol-5-yl, carboxy, —
C(O)OR2, —
C(O)NHR2, —
C(O)NHR2, —
C(O)N(R2)2, —
C(O)NR7R8, —
C(O)NHC(O)R2, —
C(O)NHC(O)NHR2, —
C(O)NHC(O)N(R2)2, —
C(O)NHC(O)NR7R8, —
C(O)NHSO2R2, —
C(O)NHSO2NHR2, —
C(O)NHSO2N(R2), —
C(O)NHSO2NR7R8, —
C(CH3)2C(O)OH, —
(CH2)yC(O)OH, wherein y is 1, 2, 3, 4, 5, or 6, —
PO2H2, —
PO3H2, —
P(R2)O2H, and phosphate, all of which can be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R2β
, R3β
, R5β
and R6β
are independently selected from the group consisting of hydrogen, nitro, alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, cycloalkylalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heteroaryl lower alkyl, heterocyclic, heterocyclic lower alkyl, alkylthioalkyl, cycloalkylthioalkyl, arylthio lower alkyl, aralkyl lower thioalkyl, heteroarylthio lower alkyl, heteroaralkyl lower thioalkyl, heterocyclicthio lower alkyl, heterocyclicalkyl lower thioalkyl, —
C(O)R2, R2C(O)alkyl, aminoalkyl, cycloalkylaminoalkyl, arylamino lower alkyl, heteroarylamino lower alkyl, heterocyclicamino lower alkyl, hydroxyl, hydroxyalkyl, alkoxy, lower alkoxy, —
(O(CH2)2)1-3—
O-lower alkyl, cycloalkyloxy, cycloalkylalkoxy, haloalkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, heteroaryl lower alkoxy, heterocyclicoxy, heterocyclicalkoxy, heterocyclic lower alkoxy, —
OC(R1)2C(O)OH, —
OC(R1)2C(O)OR2, —
OC(R1)2C(O)NH2, —
OC(R1)2C(O)NHR2, —
OC(R1)2C(O)N(R2)2, —
OC(R1)2C(O)NR7R8, amino, alkylamino, acylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, heteroarylamino, heteroaralkylamino, heterocyclicamino, heterocyclicalkylamino, —
NHR2, N(R2)2, —
NR7R8, —
NHC(R1)2C(O)OH, —
NHC(R1)2C(O)OR2, —
NHC(O)R2, —
N(R2)C(O)R2, —
NHC(O)OR2, —
NHC(O)SR2, —
NHSO2NHR2, —
NHSO2R2, —
NHSO2NR7R8, —
N(C(O)NHR2)2, —
NR2SO2R2, —
NHC(O)NHR2, —
NHC(O)NR7R8, —
NHC(O)N(R2)2, thiol, alkylthio, cycloalkylthio, cycloalkylalkylthio, haloalkylthio, arylthio, aralkylthio, heteroarylthio, heteroaralkylthio, heterocyclicthio, heterocyclicalkylthio, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, —
SC(R1)2C(O)OH, —
SC(R1)2C(O)OR2, —
SCH2C(O)OH, —
SCF2C(O)OH, —
SO2NH2, —
SO2NHR2, —
SO2N(R2)2, SO2NR7R8, —
SO2NHC(O)R2, —
SR2, —
SO2NHC(O)NHR2, —
SO2NHC(O)N(R2) 2, SO2NHC(O)NR7R8, sulfonic acid, sulfonate, sulfate, sulfinic acid, sulfenic acid, cyano, tetrazol-5-yl, carboxy, —
C(O)OR2, —
C(O)NH2, —
C(O)NHR2, —
C(O)N(R2)2, —
C(O)NR7R8, —
C(O)NHC(O)R2, —
C(O)NHC(O)NHR2, —
C(O)NHC(O)N(R2)2, —
C(O)NHC(O)NR7R8, —
C(O)NHSO2R2, —
C(O)NHSO2NHR2, —
C(O)NHSO2N(R2), —
C(O)NHSO2NR7R8, —
C(CH3)2C(O)OH, —
(CH2)yC(O)OH, wherein y is 1, 2, 3, 4, 5, or 6, —
PO2H2, —
PO3H2, —
P(R2)O2H, and phosphate, all of which can be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R1 is independently selected from the group consisting of hydrogen, lower alkyl, carbocycle, cycloalkyl, aryl, heteroaryl, heterocyclic, arylalkyl, heteroarylalkyl, and heterocyclicalkyl, wherein all may be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R1)2;
R2 is independently selected from the group consisting of alkyl, lower alkyl, alkenyl, alkynyl, carbocycle, cycloalkyl, aryl, heteroaryl, heterocyclic, arylalkyl, heteroarylalkyl, and heterocyclicalkyl, wherein all may be substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R7 and R8 are independently selected from the group consisting of alkyl, alkenyl, heteroaryl and aryl and linked together forming a 4- to 12-membered monocyclic, bicylic, tricyclic or benzofused ring;
wherein one of R2β
, R3β
, R4β
, R5β
or R6β
must be a carbon-carbon linked heteroaryl;
wherein all R1, R2, R7 and R8 substituents can be optionally substituted where possible with one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2.
-
-
25. The compound of claim 24 or its pharmaceutically acceptable salt or ester, wherein:
-
R2α
, R3α
, R4α
, R5α
, R6α
and R4β
, are independently selected from the group consisting of hydrogen, halogen, nitro, alkyl, haloalkyl, heteroaryl, heterocyclic, hydroxyl, alkoxy, haloalkoxy, heteroaryloxy, heteroarylalkoxy, heterocyclicoxy, heterocyclicalkoxy, —
OC(R1)2C(O)OH, —
OC(R1)2C(O)OR2, —
OC(R1)2C(O)NH2, —
OC(R)2C(O)NHR2, —
OC(R1)2C(O)N(R2)2, —
OC(R1)2C(O)NR7R8, heteroarylamino, heterocyclicamino, —
NHR2, N(R2)2, —
NR7R8, —
NHC(O)R2, —
N(R2)C(O)R2, —
NHC(O)OR2, —
NHSO2R2, —
NR2SO2R2, cyano, tetrazol-5-yl, carboxy, —
C(O)OR2, —
C(O)NH2, —
C(O)NHR2, —
C(O)N(R2)2, —
C(O)NR7R8, all of which can be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R2β
, R3β
, R5β
and R6β
are independently selected from the group consisting of hydrogen, heteroaryl, heterocyclic, alkyl, alkoxy, and lower alkoxy, all of which can be optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R1 is independently selected from the group consisting of hydrogen, and lower alkyl, optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R2 is independently selected from the group consisting of alkyl and lower alkyl, optionally substituted where possible by one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
R7 and R8 are independently selected from the group consisting of alkyl, alkenyl, heteroaryl and aryl and linked together forming a 4- to 12-membered monocyclic, bicylic, tricyclic or benzofused ring, optionally substituted where possible with one or more selected from the group consisting of halo, alkyl, lower alkyl, alkenyl, cycloalkyl, acyl, hydroxy, hydroxyalkyl, heterocyclic, amino, aminoalkyl, —
NR7R8, alkoxy, oxo, cyano, carboxy, carboxyalkyl, alkoxycarbonyl, —
C(O)NR7R8, and —
C(O)N(R2)2;
wherein one of R2β
, R3β
, R4β
, R5β
or R6β
must be a carbon-carbon linked heteroaryl.
-
-
26. The compound of claim 1 selected from the group consisting of:
-
4-[2-(4-Methoxy-3-thien-2-yl-phenyl)-acryloyl]-benzoic acid;
4-[2-(2-Methoxy-5-quinolin-3-yl-phenyl)-acryloyl]-benzoic acid;
2-{3-[1-(4-Carboxy-benzoyl)-vinyl]-4-methoxy-phenyl}-pyrrole-1-carboxylic acid tert-butyl ester;
4-[2-(2-Methoxy-5-pyridin-3-yl-phenyl)-acryloyl]-benzoic acid;
4-[2-(5-Benzo[b]thien-2-yl-2-methoxy-phenyl)-acryloyl]-benzoic acid;
4-[2-(2-Methoxy-5-thien-2-yl-phenyl)-acryloyl]-benzoic acid;
4-[2-(2-Methoxy-5-thien-2-yl-phenyl)-acryloyl]-benzoic acid;
4-[2-(2-Methoxy-5-thien-2-yl-phenyl)-acryloyl]-benzoic acid methyl ester;
N-(2-Hydroxy-1,1-bis-hydroxymethyl-ethyl)-4-[2-(2-methoxy-5-thien-2-yl-phenyl)-acryloyl]-benzamide;
1-[4-(4-Hydroxy-piperidine-1-carbonyl)-phenyl]-2-(2-methoxy-5-thien-2-yl-phenyl)-propenone;
1-(4-Fluoro-phenyl)-2-(2-methoxy-5-thien-2-yl-phenyl)-propenone;
2-(2-Methoxy-5-thien-2-yl-phenyl)-1-(4-pyrrolidin-1-yl-phenyl)-propenone;
1-(4-Hydroxy-phenyl)-2-(2-methoxy-5-thien-2-yl-phenyl)-propenone;
2-(2-Methoxy-5-thien-2-yl-phenyl)-1-(4-nitro-phenyl)-propenone;
N-{4-[2-(2-Methoxy-5-thien-2-yl-phenyl)-acryloyl]-phenyl}-methanesulfonamide;
N-{4-[2-(2-Methoxy-5-thien-2-yl-phenyl)-acryloyl]-phenyl}-N-methyl-methane-sulfonamide;
N-{4-[2-(2-Methoxy-5-thien-2-yl-phenyl)-acryloyl]-phenyl}-isobutyramide;
2-(2-Methoxy-5-thien-2-yl-phenyl)-1-[4-(pyrimidin-2-ylamino)-phenyl]-propenone;
2-{4-[2-(2-Methoxy-5-thien-2-yl-phenyl)-acryloyl]-phenylamino}-nicotinic acid ethyl ester;
2-{4-[2-(2-Methoxy-5-thien-2-yl-phenyl)-acryloyl]-phenylamino}-nicotinic acid;
2-(2-Methoxy-5-thien-2-yl-phenyl)-1-[4-(pyrazin-2-ylamino)-phenyl]-propenone;
3,5-Dimethyl-isoxazole-4-sulfonic acid {4-[2-(2-methoxy-5-thien-2-yl-phenyl)-acryloyl]-phenyl}-amide;
Isoxazole-5-carboxylic acid {4-[2-(2-methoxy-5-thien-2-yl-phenyl)-acryloyl]-phenyl}-amide;
1-Methyl-1H-pyrrole-2-carboxylic acid {4-[2-(2-methoxy-5-thien-2-yl-phenyl)-acryloyl]-phenyl}-amide;
4-[2-(3,4-Dimethoxy-5-thien-2-yl-phenyl)-acryloyl]-benzoic acid methyl ester;
4-[2-(3,4-Dimethoxy-5-thien-2-yl-phenyl)-acryloyl]-benzoic acid;
4-[2-(3,4-Dimethoxy-5-thien-2-yl-phenyl)-acryloyl]-N-(2-morpholin-4-yl-ethyl)-benzamide;
2-(5-Benzo[b]thien-2-yl-2,4-dimethoxy-phenyl)-1-(4-fluoro-phenyl)-propenone;
4-[2-(2,4-Dimethoxy-5-thien-2-yl-phenyl)-acryloyl]-benzoic acid;
3-[2-(2-Methoxy-5-thien-2-yl-phenyl)-acryloyl]-benzoic acid;
1-(4-tert-Butyl-phenyl)-2-(2-methoxy-5-thien-2-yl-phenyl)-propenone;
2-(2-Methoxy-5-thien-2-yl-phenyl)-1-(4-trifluoromethyl-phenyl)-propenone;
4-[2-(2-Isopropoxy-5-thien-2-yl-phenyl)-acryloyl]-benzoic acid;
4-{2-[2-(2-Oxo-2-piperidin-1-yl-ethoxy)-5-thien-2-yl-phenyl]-acryloyl}-benzoic acid;
4-{2-[2-(2-Piperidin-1-yl-ethoxy)-5-thien-2-yl-phenyl]-acryloyl}-benzoic acid hydrochloride salt; and
4-[2-(2-Methoxy-5-thien-3-yl-phenyl)-acryloyl]-benzoic acid.
-
-
27. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26, together with one or more pharmaceutically acceptable carrier.
-
28. A method for the treatment or prophylaxis of an inflammatory disorder, comprising administering an effective amount of a compound of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26.
-
29. The method of claim 28, wherein the disorder is arthritis.
-
30. The method of claim 28, wherein the disorder is rheumatoid arthritis.
-
31. The method of claim 28, wherein the disorder is asthma.
-
32. The method of claim 28, wherein the treatment is disease modifying for the treatment of rheumatoid arthritis.
-
33. The method of claim 28, wherein the disorder is allergic rhinitis.
-
34. The method of claim 28, wherein the disorder is chronic obstructive pulmonary disease.
-
35. The method of claim 28, wherein the disorder is atherosclerosis.
-
36. The method of claim 28, wherein the disorder is restinosis.
-
37. A method for inhibiting the expression of VCAM-1, comprising administering an effective amount of a compound of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26.
-
2. The compound of claim 1 or its pharmaceutically acceptable salt or ester, wherein:
-
Specification
- Resources
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeAtherogenics, Inc.
-
Original AssigneeAtherogenics, Inc.
-
InventorsWeingarten, M. David, Sikorski, James A., Hoong, Lee K., Skudlarek, Jason
-
Application NumberUS11/170,647Publication NumberTime in Patent OfficeDaysField of SearchUS Class Current514/438CPC Class CodesC07D 207/335 Radicals substituted by nit...C07D 213/50 Ketonic radicalsC07D 215/14 Radicals substituted by oxy...C07D 333/22 Radicals substituted by dou...C07D 333/56 Radicals substituted by oxy...C07D 409/10 linked by a carbon chain co...C07D 409/12 linked by a chain containin...C07D 413/12 linked by a chain containin...